GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kolon TissueGene Inc (XKRX:950160) » Definitions » Capital Expenditure

Kolon TissueGene (XKRX:950160) Capital Expenditure : ₩-77,252.58 Mil (TTM As of Dec. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Kolon TissueGene Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Kolon TissueGene's cash flow for capital expenditures for the three months ended in Dec. 2024 was ₩-24,519 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Dec. 2024 was ₩-77,252.58 Mil.

Kolon TissueGene Capital Expenditure Historical Data

The historical data trend for Kolon TissueGene's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kolon TissueGene Capital Expenditure Chart

Kolon TissueGene Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Capital Expenditure
Get a 7-Day Free Trial Premium Member Only -839.65 -6,137.00 -24,343.71 -46,197.79 -77,252.58

Kolon TissueGene Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Capital Expenditure Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -25,912.03 -10,945.57 -18,416.35 -23,371.62 -24,519.03

Kolon TissueGene Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-77,252.58 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kolon TissueGene Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kolon TissueGene Inc (XKRX:950160) » Definitions » Capital Expenditure
Comparable Companies
XKRX:298380 XKRX:302440 XKRX:145020 XKRX:141080 XKRX:310210 XKRX:214450 XKRX:096530 XKRX:086900 XKRX:087010 XKRX:358570 VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
9713 Key West Avenue, Suite 300, Rockville, MD, USA, 20850
Website
https://www.tissuegene.com
Kolon TissueGene Inc is a biopharmaceutical company that develops regenerative therapies for the treatment of various orthopedic disorders. It is developing four product candidates, TG-C, TG-B, TG-D and TG-N for regeneration of cartilage, bone, disc and nerve.

Kolon TissueGene Headlines

No Headlines